Corbus and Eli Lilly Report Positive Obesity Drug Trial Results, Driving Stock Gains
Key Insights
Corbus Pharmaceuticals' Phase 1a study of oral CRB-913 demonstrated a favorable safety profile and emerging weight loss evidence, targeting different pathways than GLP-1 (search) drugs.
Eli Lilly's late-stage trial data for retatrutide showed significant weight loss and pain relief for participants with knee osteoarthritis.
Both pharmaceutical stocks experienced notable gains, with Corbus up 2% and Eli Lilly rising 3.2% following the positive trial announcements.
Two pharmaceutical companies reported encouraging obesity drug trial results today, driving significant stock price gains and heightened investor interest in the competitive weight management therapeutics market.
Corbus Advances Novel Obesity Approach
Corbus Pharmaceuticals Holdings Inc. announced positive results from its Phase 1a study of CRB-913, an oral obesity medication that targets different pathways than the widely-used GLP-1 (search) drugs. The trial demonstrated a favorable safety profile and emerging weight loss evidence, representing a potentially differentiated approach to obesity treatment.
The small-cap biotech stock gained 2% to trade at $10.46, recovering from the $10 level after experiencing a pullback from its October 20 all-time high of $20.56. Despite recent volatility, Corbus shares have surged 62.8% over the past nine months, reflecting growing investor confidence in the company's obesity pipeline.
Eli Lilly's Dual-Benefit Results
Eli Lilly reported late-stage trial data for retatrutide showing significant weight loss outcomes alongside an unexpected additional benefit. Participants suffering from osteoarthritis of the knee experienced notable pain relief in addition to weight reduction, potentially expanding the drug's therapeutic applications beyond obesity treatment.
The pharmaceutical giant's stock rose 3.2% to $1,025.28, rebounding from recent consolidation following its November 26 all-time peak of $1,111.99. Eli Lilly shares have gained over 33% year-to-date, driven by strong performance across its obesity and diabetes drug portfolio.
Market Response and Options Activity
The positive trial announcements generated substantial options trading activity for both companies. Corbus experienced 43 times its typical intraday call volume, with the December 19 call contract emerging as the most popular choice among traders. Eli Lilly saw double its normal call trading volume, with the weekly December 12, 1,020-strike call attracting the highest interest.
Both stocks currently present attractive options trading opportunities based on volatility metrics. Corbus sports a Schaeffer's Volatility Index of 94%, ranking above only 9% of annual readings, while Eli Lilly's SVI of 30% ranks above 15% of annual readings, indicating that options are affordably priced relative to historical levels.